| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/22/2004 | US20040014141 Comprises transcription factor referred to as dragon protein (DRG) for treating and diagnosing nervous system, skin, muscle, bone and eye disorders |
| 01/22/2004 | US20040014111 Methods for the identification of IKKalpha function and other genes useful for treatment of imflammatory diseases |
| 01/22/2004 | US20040014089 Culturing a transformant in a medium, allowing the polypeptide having phospholipase a2 activity fo form and accumulating in the culture, recovering the polypeptide thus formed |
| 01/22/2004 | US20040014038 G-protein coupled receptor (GPCR) polypeptides, vectors, host cells, antibodies, and recombinant methods for producing nucleic acids/polypeptides; methods for diagnosis, treatment, and prevention of disorders involving these human proteins |
| 01/22/2004 | US20040014037 Release factors (RF-1) polypeptides and DNA (RNA) encoding RF-1 polypetides and methods for producing such polypeptides by recombinant techniques; utilizing RF-1 polypeptides to screen for antibiotics |
| 01/22/2004 | US20040013727 Hydrophilic gel foaming matrix; cellulose ethers |
| 01/22/2004 | US20040013720 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 01/22/2004 | US20040013718 Three-dimensional body; antiinflammatory agents, autoimmune diseases; in situ response; side effect reduction |
| 01/22/2004 | US20040013708 Mixture containing emulsifiers, proteins and lipophilic starch; food processing |
| 01/22/2004 | US20040013668 Polypeptide antibody which binds to low density lipoprotein; quantitative analysis |
| 01/22/2004 | US20040013640 Antitumor agents; rheumatic agents; antiarthritic agents; tissue factor protein binding to antibody |
| 01/22/2004 | US20040013637 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 01/22/2004 | DE10230752A1 Neue Arzneimittelkompositionen auf der Basis von Magnesiumsalzen und Fibrinolytika New pharmaceutical compositions based on magnesium salts and fibrinolytics |
| 01/22/2004 | DE10230381A1 Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen Use of inhibitors of alanyl-aminopeptidase, and pharmaceutical preparations comprising them |
| 01/22/2004 | DE10230272A1 AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen AT1-receptor antagonists for the prevention of secondary stroke |
| 01/22/2004 | DE10230027A1 Neue Arzneimittelkombinationen auf der Basis von Natriumkanalblockern und Magnesiumsalzen New drug combinations on the basis of sodium channel blockers and magnesium salts |
| 01/22/2004 | CA2843044A1 A process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid |
| 01/22/2004 | CA2833808A1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 01/22/2004 | CA2509821A1 3-phenyl analogs of toxoflavine as kinase inhibitors |
| 01/22/2004 | CA2493373A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 01/22/2004 | CA2492781A1 Medicinal composition for mitigating blood lipid or lowering blood homocystein |
| 01/22/2004 | CA2492720A1 A process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid |
| 01/22/2004 | CA2492669A1 Novel indoline compound and medicinal use thereof |
| 01/22/2004 | CA2492561A1 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | CA2492433A1 Organic amine salts of poorly soluble probucol esters and ethers |
| 01/22/2004 | CA2492430A1 Phenylalanine enamide derivatives |
| 01/22/2004 | CA2492427A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 01/22/2004 | CA2492421A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 01/22/2004 | CA2492387A1 Combination of an allosteric carboxylic of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/22/2004 | CA2492381A1 Phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors |
| 01/22/2004 | CA2492374A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea |
| 01/22/2004 | CA2492330A1 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 01/22/2004 | CA2492273A1 3, 10, and 12a substituted tetracycline compounds |
| 01/22/2004 | CA2492164A1 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | CA2492100A1 Substituted 2-alkylamine nicotinic amide derivatives and use there of |
| 01/22/2004 | CA2492083A1 N-sulfonylpiperidines as metalloproteinase inhibitors (tace) |
| 01/22/2004 | CA2492046A1 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 01/22/2004 | CA2492045A1 Substituted amine derivatives and methods of use |
| 01/22/2004 | CA2491655A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations |
| 01/22/2004 | CA2490818A1 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/22/2004 | CA2489084A1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 01/21/2004 | EP1382679A2 Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
| 01/21/2004 | EP1382616A2 Pharmaceutical composition for use in the treatment of abnormalities associated with the activity of a human Y5-receptor |
| 01/21/2004 | EP1382606A2 8-azabicyclo[3.2.1]octane derivatives and their use as anticholinergics |
| 01/21/2004 | EP1382605A2 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands |
| 01/21/2004 | EP1382604A1 Quinoline derivative having azolyl group and quinazoline derivative |
| 01/21/2004 | EP1382351A1 Combination therapy of agiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovasuclar disease |
| 01/21/2004 | EP1382345A2 Uses of inhibitors of hemostasis |
| 01/21/2004 | EP1382336A1 Abc expression promoters |
| 01/21/2004 | EP1382334A1 Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
| 01/21/2004 | EP1381684A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/21/2004 | EP1381681A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use |
| 01/21/2004 | EP1381631A2 Human timp-1 antibodies |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381615A2 ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H- 1,4]DIOXINO 2,3-e]INDOLE |
| 01/21/2004 | EP1381611A1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 01/21/2004 | EP1381608A1 Cyclohexylphenyl vasopressin agonists |
| 01/21/2004 | EP1381607A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepine-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists |
| 01/21/2004 | EP1381606A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 01/21/2004 | EP1381605A1 Mercaptoacetylamide derivatives, a process for their preparation and their use |
| 01/21/2004 | EP1381602A1 Heterocyclyldicarbamides as caspase inhibitors |
| 01/21/2004 | EP1381594A1 Urea compounds useful as anti-inflammatory agents |
| 01/21/2004 | EP1381592A1 1,4-disubstituted benzo-fused compounds |
| 01/21/2004 | EP1381590A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 01/21/2004 | EP1381432A2 Hsa-free formulations of interferon-beta |
| 01/21/2004 | EP1381408A2 Modular infusion device and method |
| 01/21/2004 | EP1381382A2 Methods and compositions for the treatment of diseases of the eye |
| 01/21/2004 | EP1381380A1 Pharmaceutical composition containing bulbophyllum |
| 01/21/2004 | EP1381377A2 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 01/21/2004 | EP1381376A2 In vivo use of water absorbent polymers |
| 01/21/2004 | EP1381373A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method |
| 01/21/2004 | EP1381371A2 Hormone replacement therapy |
| 01/21/2004 | EP1381365A1 Pyrrolidine sulfonamides |
| 01/21/2004 | EP1381363A1 Imidazo [1,2-a]-pyridine derivatives as mglur5 antagonists |
| 01/21/2004 | EP1381360A1 Compounds and methods for inhibiting metap2 in mammals |
| 01/21/2004 | EP1381354A2 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
| 01/21/2004 | EP1280799B1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 01/21/2004 | EP1242415B1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 01/21/2004 | EP1128826B1 Chromone enteric release formulation |
| 01/21/2004 | EP1126852B1 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 01/21/2004 | EP1019048B1 Use of an angiotensin ii receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients |
| 01/21/2004 | EP0942723B1 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators |
| 01/21/2004 | EP0914124B1 ANTITHROMBOTIC AND ANTIATHEROGENIC PHARMACEUTICAL COMPOSITION INCLUDING A THIENOPYRIDINE DERIVATIVE AND AN HMG-CoA-REDUCTASE INHIBITOR |
| 01/21/2004 | CN1469876A Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 01/21/2004 | CN1469875A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469874A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469873A Piperidine compounds as anti-allergic |
| 01/21/2004 | CN1469872A A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidine-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b] thiophene hydrochloride |
| 01/21/2004 | CN1469867A Novel phenylalanine derivatives |
| 01/21/2004 | CN1469866A New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl- pyrimidines, their preparation and application as medication |
| 01/21/2004 | CN1469864A Process for preparing cilostazol |
| 01/21/2004 | CN1469860A Aza-amino acid derivatives (factor XA-inhibitors 15) |
| 01/21/2004 | CN1469858A Aspirin-triggered lipid mediators |
| 01/21/2004 | CN1469754A Orally administered peptides to ameliorate a therosclerosis |
| 01/21/2004 | CN1469752A Method for treating the central nervous system by administration of IGF structural analogs |
| 01/21/2004 | CN1469745A Preventives and remedies for complications of diabetes |
| 01/21/2004 | CN1469743A 雌激素受体调节剂 Estrogen receptor modulators |
| 01/21/2004 | CN1469720A Radioactive emission detector with position tracking system and application in therapeutical system and treatment process |
| 01/21/2004 | CN1468860A Manyprickle acanthopanax general saponin extractive and its medicinal composition |
| 01/21/2004 | CN1468859A Longbract cattail general flavone extractive and its prepn and use |